What is the role of pyridoxine (vitamin B6) in the treatment of primary hyperoxaluria type 1?

Pyridoxine Role in Primary Hyperoxaluria

All patients with primary hyperoxaluria type 1 (PH1) should be tested for pyridoxine responsiveness, and those who respond should receive dose-titrated pyridoxine therapy as a cornerstone of treatment to reduce urinary oxalate excretion and prevent progression to kidney failure. 1

Universal Testing Recommendation

The 2023 ERKNet/OxalEurope expert consensus provides clear guidance: pyridoxine responsiveness testing is recommended in ALL patients with PH1, with dose titration based on urinary oxalate excretion 1. This applies to:

• All patients with suspected PH1 (start immediately, even before genetic confirmation)
• All patients with genetically confirmed PH1
• Patients of any age with preserved kidney function

Mechanism and Efficacy

Pyridoxine (vitamin B6) works through multiple mechanisms in PH1 2:

• Acts as a cofactor for the deficient enzyme alanine:glyoxylate aminotransferase (AGT)
• Functions as a chemical chaperone, improving enzyme folding and peroxisomal targeting
• Increases net enzyme expression and catalytic activity

Pyridoxine responsiveness is defined as >30% reduction in urinary oxalate excretion after at least 3 months of treatment 1. Approximately 50% of PH1 patients respond to pyridoxine 3.

Genotype-Response Relationship

The strongest pyridoxine responses occur in patients with specific mutations:

• p.Gly170Arg homozygous: Most responsive, can achieve near-complete normalization 4
• p.Phe152Ile: Significant response, especially when combined with the minor allele polymorphism 4
• p.Gly170Arg heterozygous: Approximately 50% reduction in oxalate 4

Other mutations showing partial response include p.Gly41Arg and p.Ile244Thr 1, 2. However, even patients without these specific mutations may respond and should be tested 3.

Dosing Protocol

Maximum recommended dose: 5 mg/kg/day 1. The guidelines explicitly reject older recommendations of up to 20 mg/kg due to:

• Lack of evidence for additional benefit above 5 mg/kg 1
• Risk of neurotoxicity with long-term high-dose therapy 1
• Formation of inactive AGT-PNP complexes at excessive doses 5

Testing protocol:

1. Start pyridoxine at 5 mg/kg/day
2. Measure urinary oxalate on at least 2 occasions after minimum 2 weeks of treatment 1
3. If responsive (>30% reduction), titrate to the lowest effective dose
4. Monitor with at least 2 urinary oxalate measurements per dose adjustment 1
5. Once optimal dose established, check urinary oxalate twice yearly 1

Clinical Impact on Outcomes

Pyridoxine responsiveness directly influences major treatment decisions:

• Kidney transplantation alone can be considered in patients with stage 5D CKD who are homozygous for pyridoxine-responsive mutations (strong recommendation) 1
• Combined liver-kidney transplantation is recommended for advanced disease (eGFR <30) in patients who do NOT respond to pyridoxine and lack access to RNAi therapy 1
• RNAi therapy eligibility requires documented pyridoxine non-responsiveness or mutations consistent with non-responsiveness 1

Remarkably, kidney failure may be reversible in pyridoxine-responsive patients: three patients homozygous for G170R recovered from dialysis with pharmacologic-dose pyridoxine (median 8.8 mg/kg/day), discontinuing hemodialysis after 5-19 months 6.

Critical Caveats

Important limitations to recognize:

• Even homozygous p.Gly170Arg patients may not achieve complete biochemical remission 3
• Pyridoxine is specific to PH1 only—PH2 and PH3 do not respond 1
• Normal urinary glycolate does not exclude PH1, so pyridoxine testing should proceed regardless 1
• Excessive pyridoxine doses can paradoxically reduce AGT activity by accumulating PNP, which competes with the active cofactor PLP 5

Alternative B6 Vitamers

Emerging evidence suggests pyridoxamine (PM) and pyridoxal (PL) may be more effective than pyridoxine because they raise intracellular PLP and PMP (active forms) without accumulating the inhibitory PNP 5. These should be investigated as potential superior therapeutics, though they are not yet part of standard guidelines.

Integration with Other Therapies

Pyridoxine should be combined with:

• Hyperhydration (3.5-4 L/day in adults; 2-3 L/m² BSA in children) 1
• Potassium citrate (0.1-0.15 g/kg) 1
• Balanced diet avoiding only extremely high-oxalate foods 1

For pyridoxine non-responders with preserved kidney function and active disease, RNAi therapy (lumasiran) becomes the next-line treatment 1.